Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Posted by Francis Steltz on Nov 3rd, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective hoisted by research analysts at The Goldman Sachs Group from $654.00 to $725.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the pharmaceutical company’s stock. The Goldman Sachs Group‘s target price would suggest a potential upside of 35.70% from the company’s current price.

Several other research analysts also recently commented on the stock. Rothschild & Co Redburn boosted their price objective on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Stifel Nicolaus raised their target price on Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a “hold” rating in a report on Tuesday. Royal Bank Of Canada upped their price objective on Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an “outperform” rating in a research report on Tuesday. TD Cowen upped their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Barclays raised their price objective on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $595.74.

Check Out Our Latest Stock Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Trading Down 3.4%

VRTX stock traded down $18.88 during mid-day trading on Tuesday, hitting $534.27. The stock had a trading volume of 1,204,990 shares, compared to its average volume of 1,388,479. The firm has a fifty day simple moving average of $523.32 and a 200 day simple moving average of $479.96. The firm has a market capitalization of $135.60 billion, a P/E ratio of 31.06, a P/E/G ratio of 2.54 and a beta of 0.28. Vertex Pharmaceuticals has a 52 week low of $403.16 and a 52 week high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business’s revenue was up 11.8% on a year-over-year basis. During the same period last year, the company posted $4.80 EPS. As a group, equities analysts expect that Vertex Pharmaceuticals will post 16.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. United Advisor Group LLC lifted its stake in shares of Vertex Pharmaceuticals by 17.4% in the 3rd quarter. United Advisor Group LLC now owns 633 shares of the pharmaceutical company’s stock valued at $331,000 after acquiring an additional 94 shares during the last quarter. Plancorp LLC bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $254,000. May Hill Capital LLC grew its position in Vertex Pharmaceuticals by 4.2% during the 3rd quarter. May Hill Capital LLC now owns 643 shares of the pharmaceutical company’s stock worth $336,000 after acquiring an additional 26 shares during the last quarter. Ashton Thomas Private Wealth LLC grew its position in Vertex Pharmaceuticals by 10.4% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 2,994 shares of the pharmaceutical company’s stock worth $1,565,000 after acquiring an additional 281 shares during the last quarter. Finally, Calamos Wealth Management LLC increased its holdings in Vertex Pharmaceuticals by 13.0% in the 3rd quarter. Calamos Wealth Management LLC now owns 1,252 shares of the pharmaceutical company’s stock worth $655,000 after purchasing an additional 144 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

Positive Sentiment: Third-quarter revenue increased 11.8% year over year to $3.44 billion, exceeding the $3.42 billion consensus estimate. Growth was supported by the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Reports Third Quarter 2026 Financial Results
Positive Sentiment: Several analysts raised their price targets after the earnings release. RBC lifted its target to $600 with an “outperform” rating, Wells Fargo raised its target to $650 with an “overweight” rating, Cantor Fitzgerald increased its target to $619 with an “overweight” rating, and Stifel raised its target to $563 while maintaining a “hold” rating. Wells Fargo analyst update
Positive Sentiment: Management raised full-year 2026 revenue guidance to $13.2 billion-$13.3 billion and highlighted continued portfolio diversification, pipeline progress, and the completed acquisition of Crinetics Pharmaceuticals. Vertex third-quarter results
Neutral Sentiment: The company’s outlook is broadly in line with Wall Street’s $13.3 billion revenue estimate, limiting the positive impact of the guidance increase. Investors will focus on whether newer launches can offset the eventual transition within the cystic fibrosis business.
Negative Sentiment: Third-quarter adjusted earnings of $4.76 per share fell short of consensus estimates ranging from $4.82 to $4.92 and declined from $4.80 a year earlier. Vertex misses third-quarter earnings estimates
Negative Sentiment: Higher investment in new product launches and the Crinetics transaction kept profit growth from matching revenue growth, creating concern that elevated spending could weigh on near-term margins.

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.